Patents Represented by Attorney Danica Hostettler

Find this attorney in the Justia Lawyer Directory

  • MGLU2 agonists
    Patent number: 8318184
    Abstract: The present invention provides novel mGlu2 agonists useful in the treatment of bipolar disorder, schizophrenia, depression, and generalized anxiety disorder.
    Type: Grant
    Filed: December 15, 2010
    Date of Patent: November 27, 2012
    Assignee: Eli Lilly and Company
    Inventors: James Allen Monn, Lourdes Prieto, Lorena Taboada Martinez, Carlos Montero Salgado, Bruce William Shaw
  • 5-(5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2-carbonitrile, pharmaceutically acceptable salts thereof, or solvate of salts
    Patent number: 8314108
    Abstract: The present invention provides an aminopyrazole compound, more particularly, or a pharmaceutically acceptable salt thereof or a solvate of the salt, that inhibits Chk1 and is useful in the treatment of cancer.
    Type: Grant
    Filed: December 10, 2009
    Date of Patent: November 20, 2012
    Assignee: Eli Lilly and Company
    Inventors: Francine S. Farouz, Ryan Coatsworth Holcomb, Ramesh Kasar, Steven Scott Myers
  • Disubstituted phthalazine hedgehog pathway antagonists
    Patent number: 8273742
    Abstract: The present invention provides novel 1,4-disubstituted phthalazine hedgehog pathway antagonists useful in the treatment of cancer.
    Type: Grant
    Filed: June 15, 2010
    Date of Patent: September 25, 2012
    Assignee: Eli Lilly and Company
    Inventors: Philip Arthur Hipskind, Bharvin Kumar Patel, Takako Wilson (nee Takakuwa)
  • Stable formulations of thiadiazole derivative
    Patent number: 8222284
    Abstract: The present invention provides formulation parameters and manufacturing conditions for stable pharmaceutical compositions comprising N-{4-(2,2-dimethyl-propionyl)-(5R)-5-[(2-ethylamino-ethanesulfonylamino)-methyl]-5-phenyl-4,5-dihydro-[1,3,4]thiadiazol-2-yl}-2,2-dimethyl-propionamide that minimize undesirable chiral conversion to the less active S enantiomeric form.
    Type: Grant
    Filed: July 7, 2008
    Date of Patent: July 17, 2012
    Assignees: Eli Lilly and Company, Kyowa Hakko Kirin Co., Ltd.
    Inventors: Hiroko Kusano, Dinesh Shyamdeo Mishra, Yoshikazu Tashiro, Yosuke Watanabe, Hong Zhuang
  • Methods of treatment using a prodrug of an excitatory amino acid
    Patent number: 8153683
    Abstract: This invention relates to synthetic excitatory amino acid prodrugs and processes for their preparation. The invention further relates to methods of using, and pharmaceutical compositions comprising, the compounds for the treatment of neurological disorders and psychiatric disorders.
    Type: Grant
    Filed: May 4, 2011
    Date of Patent: April 10, 2012
    Assignee: Eli Lilly and Company
    Inventors: Eric David Moher, James Allen Monn
  • Heteroaryl urea derivatives useful for inhibiting CHK1
    Patent number: 8093244
    Abstract: Substituted urea compounds useful in the treatment of diseases and conditions related to DNA damage or lesions in DNA replication are disclosed. Methods of making the compounds, and their use as therapeutic agents, for example, in treating cancer and other diseases characterized by defects in DNA replication, chromosome segregation, or cell division, also are disclosed.
    Type: Grant
    Filed: March 29, 2006
    Date of Patent: January 10, 2012
    Assignee: ICOS Corporation
    Inventors: Frank Diaz, Francine S. Farouz, Ryan Coatsworth Holcomb, Edward A. Kesicki, Kimba Lee Fischer, Adam Wade Cook
  • Disubstituted phthalazine hedgehog pathway antagonists
    Patent number: 7981892
    Abstract: The present invention provides novel 1,4-disubstituted phthalazine hedgehog pathway antagonists useful in the treatment of cancer.
    Type: Grant
    Filed: April 1, 2009
    Date of Patent: July 19, 2011
    Assignee: Eli Lilly and Company
    Inventors: Philip Arthur Hipskind, Takako Wilson (nee Takakuwa)
  • Methods of treatment using a prodrug of an excitatory amino acid
    Patent number: 7964632
    Abstract: This invention relates to synthetic excitatory amino acid prodrugs and processes for their preparation. The invention further relates to methods of using, and pharmaceutical compositions comprising, the compounds for the treatment of neurological disorders and psychiatric disorders.
    Type: Grant
    Filed: January 15, 2010
    Date of Patent: June 21, 2011
    Assignee: Eli Lilly and Company
    Inventors: Eric David Moher, James Allen Monn, Concepcion Pedregal-Tercero, Ivan Collado Caño, Jaime Gonzalo Blanco-Urgoiti
  • Protein kinase inhibitors
    Patent number: 7855211
    Abstract: The present invention provides a compound of formula (I): or a pharmaceutically acceptable salt thereof which is useful in the treatment of cell proliferative diseases.
    Type: Grant
    Filed: December 15, 2009
    Date of Patent: December 21, 2010
    Assignee: Eli Lilly and Company
    Inventors: David A Coates, Lawrence Mark Gelbert, John M. Knobeloch, Alfonso De Dios Magana, Ana De Prado Gonzalez, Miriam Filadelfa Del Prado Catalina, Maria Cristina Garcia Paredes, Eva Maria Martin De La Nava, Maria Dolores Martin Ortega Finger, Jose Antonio Martinez Perez, Ana Isabel Mateo Herranz, Carlos Perez Martinez, Concepcion Sanchez Martinez
  • Prodrugs of excitatory amino acids
    Patent number: 7671082
    Abstract: This invention relates to synthetic excitatory amino acid prodrugs and processes for their preparation. The invention further relates to methods of using, and pharmaceutical compositions comprising, the compounds for the treatment of neurological disorders and psychiatric disorders.
    Type: Grant
    Filed: March 31, 2008
    Date of Patent: March 2, 2010
    Assignee: Eli Lilly and Company
    Inventors: Eric David Moher, James Allen Monn
  • TGF-? inhibitors
    Patent number: 7511056
    Abstract: The present invention is directed to inhibitors of TGF-? of Formula I:
    Type: Grant
    Filed: November 2, 2005
    Date of Patent: March 31, 2009
    Assignee: Eli Lilly and Company
    Inventors: Clive Gideon Diefenbacher, Thomas Albert Engler, Hong-Yu Li, Sushant Malhotra, Jason Scott Sawyer, Yan Wang
  • Mixed lineage kinase modulators
    Patent number: 7511065
    Abstract: The present invention provides a compound of the formula: (Formula I); or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising an effective amount of a compound of Formula I in combination with a suitable carrier, diluent, or excipient, and methods for treating physiological disorders, particularly congestive heart disease, comprising administering to a patient in thereof an effective amount of a compound of Formula I.
    Type: Grant
    Filed: November 12, 2003
    Date of Patent: March 31, 2009
    Assignee: Eli Lilly and Company
    Inventors: Theodore Goodson, Jr., Mary Margaret Mader, John Eldon Toth, Arindam Chatterjee, Jason Scott Sawyer
  • Prodrugs of excitatory amino acids
    Patent number: 7456221
    Abstract: This invention relates to synthetic excitatory amino acid prodrugs and processes for their preparation. The invention further relates to methods of using, and pharmaceutical compositions comprising, the compounds for the treatment of neurological disorders and psychiatric disorders.
    Type: Grant
    Filed: July 5, 2007
    Date of Patent: November 25, 2008
    Assignee: Eli Lilly and Company
    Inventors: David Scott Coffey, James Allen Monn, Concepcion Pedregal-Tercero, Steven Wayne Pedersen
  • 7-phenyl-isoquinoline-5-sulfonylamino derivatives as inhibitors of akt (protein kinase B)
    Patent number: 7449477
    Abstract: The present invention relates to compounds Formula (I) as inhibitors of AKT activity, which are useful for the treatment of susceptible neoplasms and viral infections.
    Type: Grant
    Filed: November 22, 2004
    Date of Patent: November 11, 2008
    Assignee: Eli Lilly and Company
    Inventors: David Anthony Barda, Kenneth James Henry, Jr., Jianping Huang, Sajan Joseph, Ho-Shen Lin, Michael Enrico Richett
  • Inhibitors of Akt (protein kinase B)
    Patent number: 7414063
    Abstract: The present invention relates to compounds Formula (I): as inhibitors of AKT activity, which are useful for the treatment of susceptible neoplasms and viral infections.
    Type: Grant
    Filed: March 25, 2004
    Date of Patent: August 19, 2008
    Assignee: Eli Lilly and Company
    Inventors: Rima Salim Al-Awar, David Anthony Barda, Albert Gerard Dee, Kenneth James Henry, Jr., Sajan Joseph, Ho-Shen Lin, Jose Eduardo Lopez, Michael Enrico Richett, Carmen Somoza
  • Compounds as pharmaceutical agents
    Patent number: 7405299
    Abstract: The current invention relates to compounds of the formula: (Ia) and the pharmaceutically acceptable salts thereof and their use as TGF-beta signal transduction inhibitors for treating cancer and other diseases in a patient in need thereof by administration of said compounds.
    Type: Grant
    Filed: November 24, 2003
    Date of Patent: July 29, 2008
    Assignee: Eli Lilly and Company
    Inventors: Douglas Wade Beight, Timothy Paul Burkholder, Todd Vincent Decollo, Alexander Glenn Godfrey, Charles Raymond Heap, Chi-Hsin Richard King, Hong-Yu Li, William Thomas McMillen, Jason Scott Sawyer, Yan Wang, Clive Gideon Diefenbacher, Thomas Albert Engler, Sushant Malhotra, Sreenivasa Reedy Mundla
  • Prodrugs of excitatory amino acids
    Patent number: 7371872
    Abstract: This invention relates to synthetic excitatory amino acid prodrugs and processes for their preparation. The invention further relates to methods of using, and pharmaceutical compositions comprising, the compounds for the treatment of neurological disorders and psychiatric disorders.
    Type: Grant
    Filed: June 6, 2003
    Date of Patent: May 13, 2008
    Assignee: Eli Lilly and Company
    Inventors: Eric David Moher, James Allen Monn
  • Fused pyrazole derivatives as TGF-? signal transduction inhibitors for the treatment of fibrosis and neoplasms
    Patent number: 7368445
    Abstract: The disclosed invention is directed to compounds of the formula: Formula (I) and methods of using these compounds.
    Type: Grant
    Filed: February 16, 2005
    Date of Patent: May 6, 2008
    Assignee: Eli Lilly and Company
    Inventors: Hong-Yu Li, William Thomas McMillen, Yan Wang
  • Indane derivates as muscarinic receptor agonists
    Patent number: 7265246
    Abstract: The present invention relates to compounds of Formula I: I which are agonists of the M-1 muscarinic receptor
    Type: Grant
    Filed: June 23, 2004
    Date of Patent: September 4, 2007
    Assignee: Eli Lilly and Company
    Inventors: Jennifer Rebecca Allen, Stephen Andrew Hitchcock, Bin Liu, William Wilson Turner
  • Prodrugs of excitatory amino acids
    Patent number: 7256217
    Abstract: This invention relates to synthetic excitatory amino acid prodrugs according to formula (I) and processes for their preparation.
    Type: Grant
    Filed: December 14, 2001
    Date of Patent: August 14, 2007
    Assignee: Eli Lilly and Company
    Inventors: David Scott Coffey, James Allen Monn, Concepcion Pedregal-Tercero, Steven Wayne Pedersen